Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

BACKGROUND: Immune checkpoint inhibitors (ICIs) are effective for advanced hepatocellular carcinoma (HCC). However, there are few reports on the correlation between the clinical efficacy of ICIs and the development of immune-related adverse events (irAEs) in patients with HCC. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukushima, Taito, Morimoto, Manabu, Kobayashi, Satoshi, Ueno, Makoto, Uojima, Haruki, Hidaka, Hisashi, Kusano, Chika, Chuma, Makoto, Numata, Kazushi, Tsuruya, Kota, Arase, Yoshitaka, Kagawa, Tatehiro, Hattori, Nobuhiro, Ikeda, Hiroki, Watanabe, Tsunamasa, Tanaka, Katsuaki, Maeda, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Hepatobiliary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322131/
https://www.ncbi.nlm.nih.gov/pubmed/37023703
http://dx.doi.org/10.1093/oncolo/oyad090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322131/
https://www.ncbi.nlm.nih.gov/pubmed/37023703
http://dx.doi.org/10.1093/oncolo/oyad090

Ejemplares similares